TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00968669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 30 mg
Description: MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 100 mg
Description: MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 300 mg
Description: MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
Study: NCT00319020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
Study: NCT01311856

Intervention type: BEHAVIORAL
Intervention: Standard Arm (mail/telephone)
Description: Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.

Intervention type: BEHAVIORAL
Intervention: Internet Arm
Description: Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
Study: NCT01750567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
Study: NCT02376907

Intervention type: PROCEDURE
Intervention: Biliary drainage
Description: EUS-BD or ERCP
Study: NCT01628276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cog Rehab
Description: Cognitive rehab for MS patients
Study: NCT01970072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Study: NCT03373591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine TAP block
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine TAP block
Description: Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
Study: NCT03735550

Intervention type: DEVICE
Intervention: Contact thermographic breast examination device
Description: A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.

Intervention type: DEVICE
Intervention: Contact thermographic breast examination device
Description: A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.

Intervention type: DEVICE
Intervention: Contact thermographic breast examination device
Description: A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
Study: NCT03391479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: As required.
Study: NCT03927885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given open labeled placebo PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given open labeled placebo PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: Assigned to a waiting list
Study: NCT03354676

Intervention type: OTHER
Intervention: MetS+
Description: Data processing from Patient Medical Files

Intervention type: OTHER
Intervention: MetS-
Description: Data processing from Patient Medical Files
Study: NCT04102501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
Study: NCT04491500

Intervention type: BEHAVIORAL
Intervention: High attitude environment
Description: The participants will go to 4000m altitude to work for two weeks.
Study: NCT03397446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: 50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
Study: NCT04277598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APO-2
Description: APO-2: dose adjusted gel for topical administration.
Study: NCT01970072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT03015337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New physical education instructions
Study: NCT04517409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy
Description: Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment.
Study: NCT02481206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Cardioverter Defibrillator
Description: Wearable Cardioverter Defibrillator
Study: NCT02715193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Study: NCT04407247

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Given IV
Study: NCT02715193

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT02013817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Every 4 weeks, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Every 4 weeks, 3 cycles
Study: NCT01311856

Intervention type: BEHAVIORAL
Intervention: Surveys and Questionnaires
Description: 9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.

Intervention type: BEHAVIORAL
Intervention: Surveys and Questionnaires
Description: 9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
Study: NCT01984320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
Study: NCT04407247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Given IV
Study: NCT00972686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 is an experimental treatment for patients with cancer.
Study: NCT01535625

Intervention type: DEVICE
Group type: OTHER
Intervention: Momo stent
Description: Patients with PCI
Study: NCT03786783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT01984320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
Study: NCT00180843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol + ipratropium bromide nebules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nebulized saline
Study: NCT02564601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Training
Description: The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Cognitive Training
Description: The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
Study: NCT01311856

Intervention type: BEHAVIORAL
Intervention: Exercise and Diet
Description: 15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.

Intervention type: BEHAVIORAL
Intervention: Exercise and Diet
Description: 15 minutes of strength exercise every other day, \>30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
Study: NCT03592238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trier Social Stress Test for Children
Description: Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Seated Rest
Description: Children will be asked to sit quietly or read a book of their choosing.
Study: NCT04249102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Connect, Medtronic
Description: Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Diabetes Care
Description: Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
Study: NCT01778530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Intravenous infusion.
Study: NCT02563054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Study: NCT01954082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myo-Inositol 5% Injection
Description: Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: % glucose(dextrose)
Study: NCT02563054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
Study: NCT02355639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05 % ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.064 % ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum ointment
Study: NCT03499249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
Study: NCT01188005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-CPAP
Description: administration of continuous positive airway pressure through a nasal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Description: Oxygen supplementation (3L) through nasal spectacles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine
Description: Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
Study: NCT04088734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO-102
Description: Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10\^13 vg/kg
Study: NCT00379366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External ionizing radiations
Description: 14 Gy in one time
Study: NCT00583765

Intervention type: DRUG
Intervention: Regional citrate anticoagulation
Description: Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
Study: NCT02323425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
Study: NCT04277598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APO-2
Description: APO-2: dose adjusted gel for topical administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APO-2
Description: APO-2: dose adjusted gel for topical administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for topical administration.
Study: NCT02972619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Multicomponent Intervention (MCI)
Description: Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
Study: NCT02445261

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone
Description: Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
Study: NCT04277598

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for topical administration.
Study: NCT04455100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459/Itraconazole
Description: SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
Study: NCT00815880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse™ (Implantable Counterpulsation Therapy)
Description: Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
Study: NCT00287235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Study: NCT01842230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg and S-amlodipine 5mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg and S-amlodipine 5mg
Description: * Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)
Study: NCT02300831

Intervention type: OTHER
Intervention: Data Collection
Description: Non interventional prospective data collection